Buy & Sell Luminar Technologies Inc (LAZR) – Luminar Technologies Inc Price Today
Key Stats
- $14.67MMarket Cap
- Consumer CyclicalSector
- -71.06%3M Drawdown
- $393.63MEnterprise Value
- -Dividend Yield
- 40 daysTypical Hold Time
Luminar Technologies Inc (LAZR) is currently valued at a market capitalization of $14.67M, with an enterprise value of $393.63M. Over the past 52 weeks, Luminar Technologies Inc has traded between a low of $0.02 and a high of $4.76, highlighting its annual price range. Over the past three months, Luminar Technologies Inc has recorded a drawdown of -71.06%, reflecting recent price volatility. On average, investors hold Luminar Technologies Inc for approximately 40 days, indicating typical investor behavior on the platform.
About Luminar Technologies Inc
Luminar Technologies Inc is an autonomous vehicle sensor and software company with the vision to make autonomy safe and ubiquitous by delivering lidar and associated software that meets the industry's stringent performance, safety, and economic requirements. It operates its business through the following segment: (1) Autonomy Solutions and (2) Components. The majority of revenue is earned from the Autonomy Solutions segment.
Most Recent News
Bempedoic acid shows promise in lowering LDL-C in children and statin-intolerant adults, per Esperion data.
Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analy...

Rhythm Pharmaceuticals to present at major healthcare conferences in June 2026
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 8, 2026. These events will be webcast and acce...

Virax Biolabs reports positive early data for ViraxImmune™, a test for Long COVID and related syndromes.
Virax Biolabs announced encouraging early pilot data for ViraxImmune™, a blood test in development to detect Long COVID, ME/CFS, and related post-acute infection syndromes. The test showed 88% specificity and 92% positive predictive value in distingu...
